QUOTED. Dec. 7, 2018. Diana Zuckerman.
A research and patient advocacy organization was critical of the device industry's and US FDA's long-term post-market surveillance of breast implants as part of a recent study by the group of women who have had their implants removed. The preliminary results of a study released Nov. 26 by the National Center for Health Research pointed to an increase in symptoms of autoimmune and connective tissue disease among women who have had breast implants. See what Diana Zuckerman, the president for the National Center for Health Research, said about it here.
“Device registries are focused on counting the number of surgeries, rather than evaluating symptoms or other complications. The focus on surgeries and revision surgeries omits many of the outcomes that matter most to patients, and especially patients who may not have the financial resources to undergo additional surgeries.” – Diana Zuckerman, president, National Center for Health Research
Click here for a free trial of Medtech Insight